Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESLA NASDAQ:FTLF NASDAQ:GALT NASDAQ:KRRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESLAEstrella Immunopharma$0.84-5.5%$0.96$0.63▼$3.23$32.01M0.36125,419 shs40,333 shsFTLFFitLife Brands$13.19+0.8%$14.03$9.83▼$17.75$122.93M0.7618,886 shs36,748 shsGALTGalectin Therapeutics$2.80-1.8%$1.80$0.73▼$3.90$180.38M0.7416,805 shs406,858 shsKRROKorro Bio$12.66-2.4%$13.46$10.29▼$98.00$121.75M2.43107,603 shs131,782 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESLAEstrella Immunopharma-5.54%-4.06%-12.92%-0.05%-44.27%FTLFFitLife Brands+0.76%-2.30%-5.79%+11.78%-19.33%GALTGalectin Therapeutics-1.75%+33.97%+104.38%+104.38%+17.65%KRROKorro Bio-2.39%-6.77%-6.50%-5.94%-74.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationESLAEstrella Immunopharma3.1319 of 5 stars3.55.00.00.03.31.70.0FTLFFitLife Brands4.0471 of 5 stars3.73.00.00.02.71.73.1GALTGalectin Therapeutics2.2547 of 5 stars3.52.00.00.03.31.70.0KRROKorro Bio1.5233 of 5 stars3.61.00.00.01.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESLAEstrella Immunopharma 3.00Buy$16.001,813.88% UpsideFTLFFitLife Brands 3.33Buy$20.5055.42% UpsideGALTGalectin Therapeutics 3.00Buy$6.00114.29% UpsideKRROKorro Bio 3.29Buy$102.43709.07% UpsideCurrent Analyst Ratings BreakdownLatest ESLA, GALT, KRRO, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AFTLFFitLife Brands$64.47M1.92$1.02 per share12.92$3.93 per share3.36GALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AKRROKorro Bio$4.82M24.66N/AN/A$17.12 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-1,132.38%-273.91%N/AFTLFFitLife Brands$8.98M$0.8415.7011.99N/A13.85%25.59%15.26%N/AGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)KRROKorro Bio-$83.58M-$9.44N/AN/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)Latest ESLA, GALT, KRRO, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GALTGalectin Therapeutics-$0.16N/AN/AN/AN/AN/A8/12/2025Q2 2025KRROKorro Bio-$2.54N/AN/AN/A$0.41 millionN/A5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESLAEstrella ImmunopharmaN/A0.220.22FTLFFitLife Brands0.191.640.72GALTGalectin TherapeuticsN/A0.080.08KRROKorro BioN/A9.419.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESLAEstrella Immunopharma0.35%FTLFFitLife Brands2.32%GALTGalectin Therapeutics11.68%KRROKorro Bio13.18%Insider OwnershipCompanyInsider OwnershipESLAEstrella Immunopharma55.10%FTLFFitLife Brands61.40%GALTGalectin Therapeutics50.10%KRROKorro Bio4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableKRROKorro Bio709.39 million8.96 millionNo DataESLA, GALT, KRRO, and FTLF HeadlinesRecent News About These CompaniesKorro Bio, Inc. (KRRO) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comKorro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by AnalystsJune 28, 2025 | marketbeat.comKorro to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)May 14, 2025 | theglobeandmail.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Bio to Cut 20% of WorkforceMay 7, 2025 | marketwatch.comKorro Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight RecommendationApril 30, 2025 | msn.comChardan Capital Initiates a Buy Rating on Korro Bio (KRRO)April 17, 2025 | markets.businessinsider.comKorro Bio initiated with a Buy at ChardanApril 17, 2025 | markets.businessinsider.comChardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy RecommendationApril 17, 2025 | msn.comPiper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)April 11, 2025 | markets.businessinsider.comKorro Bio appoints Loic Vincent as Chief Scientific OfficerApril 2, 2025 | markets.businessinsider.comKorro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific OfficerApril 1, 2025 | globenewswire.comKorro Bio: Promising Early Stage RNA Editing CompanyMarch 28, 2025 | seekingalpha.comKorro Bio Reports 2024 Financial Results and ProgressMarch 20, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)March 20, 2025 | markets.businessinsider.comKorro Bio, Inc.: Korro Reports Full Year 2024 Financial Results and Provides Business UpdatesMarch 19, 2025 | finanznachrichten.deIs Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth?March 19, 2025 | uk.finance.yahoo.comRBC Capital Remains a Buy on Korro Bio (KRRO)March 19, 2025 | markets.businessinsider.comKorro Bio price target lowered to $95 from $105 at RBC CapitalMarch 19, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla’s Robotaxi Hype Fuels Bullish Price Targets to $500By Sam Quirke | June 30, 2025View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?By Nathan Reiff | June 20, 2025View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionTesla Stock Could Accelerate on New EV Tax LegislationBy Gabriel Osorio-Mazilli | July 9, 2025View Tesla Stock Could Accelerate on New EV Tax LegislationTesla: The Next Month Could Make or Break the YearBy Sam Quirke | June 27, 2025View Tesla: The Next Month Could Make or Break the YearESLA, GALT, KRRO, and FTLF Company DescriptionsEstrella Immunopharma NASDAQ:ESLA$0.84 -0.05 (-5.54%) Closing price 07/15/2025 03:58 PM EasternExtended Trading$0.84 +0.01 (+0.72%) As of 07/15/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.FitLife Brands NASDAQ:FTLF$13.19 +0.10 (+0.76%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$13.63 +0.44 (+3.33%) As of 07/15/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Galectin Therapeutics NASDAQ:GALT$2.80 -0.05 (-1.75%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.87 +0.07 (+2.64%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Korro Bio NASDAQ:KRRO$12.66 -0.31 (-2.39%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$13.02 +0.37 (+2.88%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
